Winogrand et al. reported the relevance between the presence of PD-L1+ circulating tumor cells (CTCs) and favorable immunotherapy outcome (n = 10); however, it was also a negative prognostic biomarker and an overall survival predictor (n = 87) [89]. This evidence concerns the gene CD274 and neoplasm.